Bottom line
MRRGX vs AGTHX: the short answer
MRRGX (Meridian Growth Fund) and AGTHX (Growth Fund Of America) are both mutual funds.
But AGTHX is far broader, holding 335 positions to 91 for MRRGX, so beyond the top names it adds exposure MRRGX doesn't have.
AGTHX is cheaper at 0.58% vs 0.92% — a difference of $34 a year per $10,000 invested.
Over five years, AGTHX returned +10.5% a year vs −1.3% for MRRGX.
AGTHX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
MRRGX vs AGTHX side by side
| MRRGX | AGTHX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Meridian | American Funds (Capital Group) |
| Category | Large Growth | Large Growth |
| Expense ratio | 0.92% | 0.58% |
| Annual cost per $10k | $92 | $58 |
| 10-yr cost on $10k (prospectus) | $1,130 | $1,259 |
| Max front load | 0% | 5.75% |
| 12b-1 fee | — | 0.24% |
| 1-yr return | −6.3% | +13.0% |
| 5-yr return (annualized) | −1.3% | +10.5% |
| 10-yr return (annualized) | +7.4% | +14.5% |
| Best quarter | — | +26.1% |
| Worst quarter | — | −21.9% |
| Net assets (fund) | $542.9M | $360.9B |
| Number of holdings | 91 | 335 |
| Portfolio turnover | 49% | 39% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
MRRGX and AGTHX share none of their top holdings.
MRRGX top 10
- Stit Govt And Agency Inst — 4.17%
- Rb Global Inc — 2.49%
- Curtiss-wright Corp — 2.46%
- Axogen Inc — 2.43%
- Federal Signal Corp — 2.36%
- Hinge Health Inc — 2.29%
- Definium Therapeutics Inc — 2.20%
- Veracyte Inc — 2.14%
- Standardaero Inc — 2.09%
- Turning Point Brands Inc — 2.08%
AGTHX top 10
- Nvidia Corp — 6.08%
- Broadcom Inc — 5.08%
- Microsoft Corp — 4.14%
- Meta Platforms Inc — 4.07%
- Amazon.com Inc — 3.90%
- Alphabet Inc — 3.03%
- Alphabet Inc — 2.96%
- Eli Lilly And Co — 2.91%
- Micron Technology Inc — 2.65%
- Tesla Inc — 2.50%
FAQ
What is the difference between MRRGX and AGTHX?
Which is cheaper, MRRGX or AGTHX?
Should I own both MRRGX and AGTHX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.